|Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls|
Wellcome Trust Case Control Consortium
Nature 447 (7145), 661, 2007
|Identification of the breast cancer susceptibility gene BRCA2|
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, ...
Nature 378 (6559), 789-792, 1995
|Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies|
A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ...
The American Journal of Human Genetics 72 (5), 1117-1130, 2003
|Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families|
D Ford, DF Easton, M Stratton, S Narod, D Goldgar, P Devilee, DT Bishop, ...
The American Journal of Human Genetics 62 (3), 676-689, 1998
|Patterns of somatic mutation in human cancer genomes|
C Greenman, P Stephens, R Smith, GL Dalgliesh, C Hunter, G Bignell, ...
Nature 446 (7132), 153-158, 2007
|Genome-wide association study identifies novel breast cancer susceptibility loci|
DF Easton, KA Pooley, AM Dunning, PDP Pharoah, D Thompson, ...
Nature 447 (7148), 1087-1093, 2007
|Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13|
R Wooster, SL Neuhausen, J Mangion, Y Quirk, D Ford, N Collins, ...
Science 265 (5181), 2088-2090, 1994
|Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease|
B Ravikumar, C Vacher, Z Berger, JE Davies, S Luo, LG Oroz, F Scaravilli, ...
Nature genetics 36 (6), 585-595, 2004
|Risks of cancer in BRCA1-mutation carriers|
D Ford, DF Easton, DT Bishop, SA Narod, DE Goldgar
The Lancet 343 (8899), 692-695, 1994
|Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.|
DF Easton, D Ford, DT Bishop
American journal of human genetics 56 (1), 265, 1995
|Polychemotherapy for early breast cancer: an overview of the randomised trials|
Early Breast Cancer Trialists' Collaborative Group
The Lancet 352 (9132), 930-942, 1998
|International network of cancer genome projects|
International Cancer Genome Consortium
Nature 464 (7291), 993, 2010
|Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.|
DF Easton, DT Bishop, D Ford, GP Crockford
American journal of human genetics 52 (4), 678, 1993
|The landscape of cancer genes and mutational processes in breast cancer|
PJ Stephens, PS Tarpey, H Davies, P Van Loo, C Greenman, DC Wedge, ...
Nature 486 (7403), 400-404, 2012
|Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.|
PR Burton, DG Clayton, LR Cardon, N Craddock, P Deloukas, ...
Nature genetics 39 (11), 1329-1337, 2007
|Cancer incidence in BRCA1 mutation carriers|
D Thompson, DF Easton
Journal of the National Cancer Institute 94 (18), 1358-1365, 2002
|Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations|
CHEK2-Breast Cancer Consortium
Nature genetics 31 (1), 55, 2002
|Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands|
DE Goldgar, DF Easton, LA Cannon-Albright, MH Skolnick
JNCI: Journal of the National Cancer Institute 86 (21), 1600-1608, 1994
|Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial|
T Powles, R Eeles, S Ashley, D Easton, J Chang, M Dowsett, A Tidy, ...
The lancet 352 (9122), 98-101, 1998
|Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers|
KB Kuchenbaecker, JL Hopper, DR Barnes, KA Phillips, TM Mooij, ...
Jama 317 (23), 2402-2416, 2017